Sacral neuromodulation versus personalized conservative treatment in patients with idiopathic slow-transit constipation: study protocol of the No.2-trial, a multicenter open-label randomized controlled trial and cost-effectiveness analysis.

Cast your vote
 
Your vote was cast
Thank you for your feedback
Authors
Heemskerk, S C M
Rotteveel, A H
Benninga, M A
Baeten, C I M
Masclee, A A M
Melenhorst, J
van Kuijk, S M J
Dirksen, C D
Breukink, S O
Type
Article
Language
en

Metadata
Show full item record
Title
Sacral neuromodulation versus personalized conservative treatment in patients with idiopathic slow-transit constipation: study protocol of the No.2-trial, a multicenter open-label randomized controlled trial and cost-effectiveness analysis.
Published in
Int J Colorectal Dis 2018; 33(4):493-501
Publiekssamenvatting
The evidence regarding the (cost-)effectiveness of sacral neuromodulation (SNM) in patients with therapy-resistant idiopathic slow-transit constipation is of suboptimal quality. The Dutch Ministry of Health, Welfare and Sports has granted conditional reimbursement for SNM treatment. The objective is to assess the effectiveness, cost-effectiveness, and budget impact of SNM compared to personalized conservative treatment (PCT) in patients with idiopathic slow-transit constipation refractory to conservative treatment.
DOI
10.1007/s00384-018-2978-x
PMID
29470731
URI
http://hdl.handle.net/10029/621458
Collections